2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Angiotensin-converting Enzyme (ACE)

Angiotensin-converting Enzyme (ACE)

Angiotensin-converting Enzyme (ACE)

Related Products

PDF 1.4 MB

Angiotensin-converting enzyme (ACE) indirectly increases blood pressure by causing blood vessels to constrict. ACE does that by converting angiotensin I to angiotensin II, which constricts the vessels. ACE, angiotensin I and angiotensin II are part of the renin-angiotensin system (RAS), which controls blood pressure by regulating the volume of fluids in the body. ACE is secreted in the lungs and kidneys by cells in the endothelium (inner layer) of blood vessels. It has two primary functions: ACE catalyses the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor in a substrate concentration-dependent manner. ACE degrades bradykinin, a potent vasodilator, and other vasoactive peptides. These two actions make ACE inhibition a goal in the treatment of conditions such as high blood pressure, heart failure, diabetic nephropathy, and type 2 diabetes mellitus. Inhibition of ACE (by ACE inhibitors) results in the decreased formation of angiotensin II and decreased metabolism of bradykinin, leading to systematic dilation of the arteries and veins and a decrease in arterial blood pressure.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-161070
    Antiviral agent 46
    		Inhibitor
    Antiviral agent 46 (compound 4) is a derivative of cannabidiol (CBD) with anti-SARS-CoV-2 (IC50: 1.90 μM) and ACE2 activity (IC50: 1.37 μM).
    Antiviral agent 46
  • HY-B0477AS2
    Quinapril-d4
    		Inhibitor
    Quinapril-d4 (CI-906-d4) is deuterium labeled Quinapril. Quinapril is a potent, orally active, non-peptide and nonsulfhydryl inhibitor of angiotensin-converting enzyme (ACE). Quinapril specifically interrupts the conversion of angiotensin I to angiotensin II in both plasma and tissue. Quinapril is enzymatically hydrolyzed to a pharmacologically active diacid form quinaprilat. Quinapril is efficacious in hypertensive models.
    Quinapril-d<sub>4</sub>
  • HY-100713S
    Temocapril-d5
    		Inhibitor
    Temocapril-d5 is the deuterium labeled Temocapril. Temocapril is an angiotensin-converting enzyme (ACE) inhibitor. Temocapril hydrochloride can be used for the research of hypertension, congestive heart failure, acute myocardial infarction, insulin resistance, and renal diseases[1][2].
    Temocapril-d<sub>5</sub>
  • HY-A0043AR
    Cilazapril (monohydrate) (Standard)
    		Inhibitor
    Cilazapril (monohydrate) (Standard) is the analytical standard of Cilazapril (monohydrate). This product is intended for research and analytical applications.
    Cilazapril (monohydrate) (Standard)
  • HY-127026S
    Quinaprilat-d5
    		Inhibitor
    Quinaprilat-d5 is a deuterium-labeled Quinaprilat. Quinaprilat is a nonsulfhydryl ACE inhibitor, the active diacid metabolite of Quinapril. Quinaprilat specifically blocks the conversion of angiotensin I to the vasoconstrictor angiotensin II and inhibits bradykinin degradation. Quinaprilat primarily acts as a vasodilator, decreasing total peripheral and renal vascular resistance[1].
    Quinaprilat-d<sub>5</sub>
  • HY-A0113
    Cilazaprilat
    Cilazaprilat is an inhibitor of angiotensin-converting enzyme (ACE; IC50=0.7 nM for the rat enzyme) and an active metabolite of Cilazapril (HY-A0043). It decreases creatine kinase release in primary neonatal rat cardiac myocytes in an in vitro model of ischemia-reperfusion injury induced by hypoxia and reoxygenation when used at a concentration of 10 μM.3 Intra-arterial administration of cilazaprilat (3 μg/kg per minute) increases coronary blood flow and fractional shortening in a dog model of coronary hypoperfusion-induced myocardial ischemia.
    Cilazaprilat
  • HY-P10391
    Ser-Ala-Pro
    		Inhibitor
    Ser-Ala-Pro is an X-Pro structure specific angiotensin-converting enzyme (ACE) inhibitory peptide. Ser-Ala-Pro has the potential for hypertension research.
    Ser-Ala-Pro
  • HY-B0690S
    Fosinopril-d5
    		Inhibitor
    Fosinopril-d5 (SQ28555-d5 (free acid)) is deuterium labeled Fosinopril. Fosinopril (SQ28555 free acid) is the ester proagent of angiotensin-converting enzyme (ACE) inhibitor with an IC50 value of 0.18 μM. Fosinopril demonstrates a non-competitive inhibition effect on ACE activity with an Ki value of 1.675 μM.
    Fosinopril-d<sub>5</sub>
  • HY-B0130S
    Perindopril-d4 erbumine
    		Inhibitor
    Perindopril-d4 t-butylamine salt is the deuterium labeled Perindopril t-butylamine salt. Perindopril t-butylamine salt is a long-acting ACE inhibitor of which is used to treat high blood pressure, heart failure or stable coronary artery disease.
    Perindopril-d<sub>4</sub> erbumine
  • HY-B0279R
    Ramipril (Standard)
    		Inhibitor
    Ramipril (Standard) is the analytical standard of Ramipril. This product is intended for research and analytical applications. Ramipril (HOE-498) is an angiotensin-converting enzyme (ACE) inhibitor with IC50 of 5 nM.
    Ramipril (Standard)
  • HY-137361
    Ramiprilat diketopiperazine
    		Control
    Ramiprilat diketopiperazine (Ramipril diketopiperazine acid; Impurity K) is an impurity of Ramiprilat (HY-A0115). Ramiprilat, an active metabolite of Ramipril (HY-B0279), is a potent and orally active angiotensin converting enzyme (ACE) inhibitor.
    Ramiprilat diketopiperazine
  • HY-50761
    Libenzapril
    		Inhibitor
    Libenzapril (Abutapril; CGS-16617) is an orally active, potent direct-acting angiotensin-converting-enzyme (ACE) inhibitor. Libenzapril has the potential for ischemia-induced heart failure research.
    Libenzapril
  • HY-B0368S1
    Captopril-13C5,15N
    		Inhibitor
    Captopril-13C5,15N (SQ 14225-13C5,15N) is 13C and 15N labeled Captopril. Captopril (SQ 14225), antihypertensive agent, is a thiol-containing competitive, orally active angiotensin-converting enzyme (ACE) inhibitor (IC50=0.025 μM) and has been widely used for research of hypertension and congestive heart failure. Captopril is also a New Delhi metallo-β-lactamase-1 (NDM-1) inhibitor with an IC50 of 7.9 μM.
    Captopril-<sup>13</sup>C<sub>5</sub>,<sup>15</sup>N
  • HY-B1433S
    Perindoprilat-d3 disodium
    		Inhibitor
    Perindoprilat-d3 disodium is deuterated labeled Perindoprilat (HY-B1433). Perindoprilat (S 9780) is an angiotensin-converting enzyme (ACE) inhibitor with the IC50 value ranging from 1.5 to 3.2 nM. Perindoprilat can be used in hypertension research.
    Perindoprilat-d<sub>3</sub> disodium
  • HY-100713R
    Temocapril (Standard)
    		Inhibitor
    Temocapril (Standard) is the analytical standard of Temocapril. This product is intended for research and analytical applications. Temocapril is an orally active angiotensin-converting enzyme (ACE) inhibitor. Temocapril can be used for the research of hypertension, congestive heart failure, acute myocardial infarction, insulin resistance, and renal diseases.
    Temocapril (Standard)
  • HY-B0592S2
    rac-Trandolapril-d5
    		Inhibitor
    rac-Trandolapril-d5 (rac-RU44570-d5) is deuterium labeled Trandolapril. Trandolapril (RU44570) is a nonsulfhydryl proagent that is hydrolysed to the active diacid Trandolaprilat. Trandolapril is an orally administered angiotensin converting enzyme (ACE) inhibitor that has been used in the treatment of hypertension and congestive heart failure (CHF), and after myocardial infarction (MI).
    rac-Trandolapril-d<sub>5</sub>
  • HY-B0378AR
    Moexipril (hydrochloride) (Standard)
    		Inhibitor
    Moexipril (hydrochloride) (Standard) is the analytical standard of Moexipril (hydrochloride). This product is intended for research and analytical applications. Moexipril hydrochloride (RS-10085) is an orally active inhibitor of angiotensin-converting enzyme (ACE), and becomes effective by being hydrolyzed to moexiprila (hydrochloride). Moexipril hydrochloride exhibits antihypertensive and neuroprotective effects-.
    Moexipril (hydrochloride) (Standard)
  • HY-133829
    Zofenoprilat
    		Inhibitor
    Zofenoprilat is an orally active inhibitor for angiotensin converting enzyme (ACE) with an IC50 of 1.7 nM. Zofenoprilat inhibits the expression of angiotensin II, reduces the blood pressure, exhibits thus cardioprotective and renalprotective activity. Zofenoprilat promotes the NO production, decreases endothelin-1 (ET-1) expression, exhibits protective effect on vascular endothelial function. Zofenoprilat regulates oxidative stress-related molecules, exhibits antioxidant activity.
    Zofenoprilat
  • HY-101681
    Utibapril
    		Inhibitor
    Utibapril is an angiotensin-converting enzyme (ACE) inhibitor with antihypertensive activities.
    Utibapril
  • HY-101577
    NCX899
    		Inhibitor
    NCX899 is a NO-releasing derivative of enalapril, and shows inhibitory activity against angiotensin-converting enzyme (ACE) activity.
    NCX899
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity